Which statement is NOT a stated benefit of interactions between pharmaceutical companies and health care professionals?

Which statement is NOT a stated benefit of interactions between pharmaceutical companies and health care professionals?

• A. Decrease patient safety monitoring
• B. Help advance appropriate patient use
• C. Facilitate communication with third-party payers to effectively control the costs of products
• D. Ensure HCPs have the latest and most accurate available data

Answer: (A)

Engagements between pharmaceutical companies and health care professionals are aimed at supporting safe, appropriate use of medicines and keeping clinicians informed with current, accurate data. The statement that would not be a stated benefit is decreasing patient safety monitoring. In practice, these interactions are expected to strengthen pharmacovigilance—ensuring adverse events are reported, safety information is updated, and monitoring continues to protect patients. The other statements reflect legitimate benefits. Helping advance appropriate patient use means providing evidence-based information that guides correct prescribing and dosing. Facilitating communication with third-party payers to control costs relates to sharing value and real-world impact data to support coverage decisions and improve patient access. Ensuring HCPs have the latest and most accurate data keeps clinicians informed about new findings, labeling changes, and safety updates, supporting better clinical decisions.

Engagements between pharmaceutical companies and health care professionals are aimed at supporting safe, appropriate use of medicines and keeping clinicians informed with current, accurate data. The statement that would not be a stated benefit is decreasing patient safety monitoring. In practice, these interactions are expected to strengthen pharmacovigilance—ensuring adverse events are reported, safety information is updated, and monitoring continues to protect patients.

The other statements reflect legitimate benefits. Helping advance appropriate patient use means providing evidence-based information that guides correct prescribing and dosing. Facilitating communication with third-party payers to control costs relates to sharing value and real-world impact data to support coverage decisions and improve patient access. Ensuring HCPs have the latest and most accurate data keeps clinicians informed about new findings, labeling changes, and safety updates, supporting better clinical decisions.